表紙:ポリメラーゼ連鎖反応 (PCR) 市場 - 成長、傾向、および予測(2021年 - 2026年)

ポリメラーゼ連鎖反応 (PCR) 市場 - 成長、傾向、および予測(2021年 - 2026年)

Polymerase Chain Reaction Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 120 Pages | 納期: 2-3営業日

価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.81円
ポリメラーゼ連鎖反応 (PCR) 市場 - 成長、傾向、および予測(2021年 - 2026年)
出版日: 2021年07月01日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 120 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 目次

ポリメラーゼ連鎖反応 (PCR)市場の成長の主な要因には、臨床診断における用途の拡大、個別化i医療および精密医療に対する需要の高まり、ならびに医薬品開発における技術の進歩および用途が挙げられます。



第1章 イントロダクション

  • 研究成果
  • 調査の前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場のダイナミクス

  • 市場概況
  • 市場成長要因
    • 臨床診断における用途の拡大
    • 個別化医療および精密医療に対する需要の高まり
    • 医薬品開発における技術の進歩と応用
  • 市場阻害要因
    • 機器の高コスト
    • 代替技術の出現
  • ポーターファイブフォース分析
    • 新規参入の脅威
    • バイヤー/消費者の交渉力
    • サプライヤーの交渉力
    • 代替製品の脅威
    • 業界の競争

第5章 市場セグメント

  • 製品別
    • 装置
    • 試薬および消耗品
    • ソフトウェア
  • 用途別
    • 臨床診断
    • ライフサイエンス研究と産業用途
    • その他の用途
  • エンドユーザー別
    • 学術機関
    • 臨床診断検査室および病院
    • 製薬およびバイオテクノロジー産業
    • その他の
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東およびアフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Abbott Laboratories
    • Agilent Technologies, Inc.
    • Becton, Dickinson and Company
    • bioMerieux SA
    • Bio-Rad Laboratories Inc.
    • GE Healthcare
    • Merck KGaA
    • PerkinElmer Inc.
    • Promega Corporation
    • Siemens Healthcare
    • Thermo Fisher Scientific Inc.

第7章 市場機会および今後の動向

Product Code: 64490

The polymerase chain reaction market was valued at approximately USD 5,170.37 million in 2020, and it is expected to reach USD 8,094 million by 2026, registering a CAGR of 7.83% during the forecast period, 2021-2026.

The major factors driving the growth of the polymerase chain reaction market include the increasing application in clinical diagnostics, rising demand for personalized and precision medicine, and technological advancements and applications in drug development.

There is a positive impact on the PCR market due to the increasing demand in the clinical diagnostic segment of the market. As the authorities have not recommended the viral culture tests, almost all the diagnostic tests use RT-PCR to test the population who have symptoms of COVID 19 and are advised by healthcare professionals to undergo a diagnostic test.

Furthermore, the polymerase chain reaction is also gaining higher importance in the molecular diagnosis of infectious and genetic diseases with the advent of COVID-19. To facilitate personalized medicine, it is crucial to develop precise and reproducible means of gaining molecular information about the underlying disease, which can be used to guide clinical decision making, with PCR techniques being increasingly utilized in such methods. Therefore, increasing the focus on personalized medicine and patient-centered approach is driving the growth of the market studied.

Personalized medicine, which aims to provide tailor-made therapies to individual patients, depending on the molecular basis of disease, became popular over recent years. The aging global population and the rising prevalence of chronic disease are putting unrelenting pressure on the healthcare system's capacity and financial viability across the world.

According to the World Population Prospects: the 2019 Revision, one in every six people will be over 65 years of age by 2050. The rising demand for personalized medicine has thus created tremendous opportunities in the field of genetic medicine. To gain a competitive advantage in the emerging field of personalized medicine, biotechnology, and pharmaceutical firms are exploring the grounds of genomic medicine and direct-to-consumer genetic testing. To develop these products, the industry is ramping up the R&D process in the areas of biotechnology, where the polymerase chain reaction finds its major applications.

Personalized medicine thus holds the promise of providing better patient care and a high safety margin while also lowering the total healthcare costs. Therefore, the increasing geriatric population, demand for personalized medicine, and the role PCR play in developing them boost the market growth.

Key Market Trends

The Clinical Diagnostics Segment is Expected to Witness Good Growth over the Forecast Period

PCR-based molecular diagnostic tests are increasingly being used to guide patient management, particularly in the fields of infectious diseases, cancer, and congenital abnormalities. Globally, the prevalence of genetic, infectious, and chronic diseases, coupled with the increased availability of genetic and genomic information, is on the rise, and it has led to the rapid incorporation of PCR techniques in clinical laboratories.

The rising COVID-19 cases and spread of the disease in major countries have increased the demand for the diagnostic tests of the virus in the suspected population. This trend is primarily due to the low or non-availability of rapid or specific diagnostic tests for such diseases. Therefore, pertaining to broad applications of PCR in clinical diagnostics, the segment is likely to register high growth during the forecast period.

The high specificity, sensitivity, and low sample requirement make PCR-based molecular assay a go-to technique for the purpose of clinical diagnosis. PCR-based molecular assays are becoming the primary mode of diagnosis for the detection of pathogens in case of a rapid disease outbreak, such as the recent Zika and coronavirus outbreaks.

North America is Expected to Dominate the Market over the Forecast Period

The increasing prevalence of genetic and chronic disorders, such as cancer, the aging population, the rising demand for precision and personalized medicine, and favorable government initiatives are the primary factors driving the growth of the market.

As the COVID-19 cases are increasing rapidly and the spread of the virus is very rapid, speeding up the transmission. The increasing count of suspects increases the number of diagnostic tests, boosting the market growth in the country.

Pixel by LabCorp COVID-19 is a home collection test kit where the patient can self-collect nasal swab specimens at home when approved by a healthcare provider to be appropriate based on the results of a COVID-19 questionnaire. The specimen is collected carefully and sent back to the lab for RT-PCR, where the results are produced and sent back. Due to such advancements in the country, it has a cutting edge over others in the market.

In February 2020, the Department of Health and Human Services also announced the authorization of the emergency use of diagnostics for the detection of COVID-19. This authorization has increased the number of diagnostics product launches in the region.

There is also a growing trend of genetic engineering and genomic research in academia and biotechnology industries of the United States. Increasing genomic research is primarily fueled by the high demand for targeted and precision medicine for the management of chronic disorders, as well as due to the need for understanding the genetic and molecular basis of the disease. In recent years, several government initiatives were launched, which are supplementing the growth of the PCR market.

Competitive Landscape

The market studied is moderately consolidated in nature, owing to the presence of a few major players. Some of the market players are Abbott Laboratories, Agilent Technologies Inc., Becton, Dickinson and Company, bioMerieux SA, Bio-Rad Laboratories Inc., GE Healthcare, Merck KGaA, PerkinElmer Inc., Promega Corporation, Siemens Healthcare, and Thermo Fisher Scientific Inc. These major companies are found focusing on R&D to develop advanced technology products to gain a competitive edge. Companies are also found engaging in partnerships, mergers, and acquisitions, aiming to strengthen their product portfolios and manufacturing capacities and provide competitive differentiation.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support



  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Application in Clinical Diagnostics
    • 4.2.2 Rising Demand for Personalized and Precision Medicines
    • 4.2.3 Technological Advancements and Applications in Drug Development
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Instruments
    • 4.3.2 Emergence of Alternative Technologies
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Product
    • 5.1.1 Instruments
      • Standard PCR Systems
      • Digital PCR Systems
      • Real-time PCR Systems
    • 5.1.2 Reagents and Consumables
    • 5.1.3 Software
  • 5.2 By Application
    • 5.2.1 Clinical Diagnostics
    • 5.2.2 Life Science Research and Industrial Applications
    • 5.2.3 Other Applications
  • 5.3 By End User
    • 5.3.1 Academic Institutes
    • 5.3.2 Clinical Diagnostics Labs and Hospitals
    • 5.3.3 Pharmaceutical and Biotechnology Industries
    • 5.3.4 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
      • United States
      • Canada
      • Mexico
    • 5.4.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.4.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • GCC
      • South Africa
      • Rest of Middle-East and Africa
    • 5.4.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Agilent Technologies Inc.
    • 6.1.3 Becton, Dickinson and Company
    • 6.1.4 bioMerieux SA
    • 6.1.5 Bio-Rad Laboratories Inc.
    • 6.1.6 GE Healthcare
    • 6.1.7 Merck KGaA
    • 6.1.8 PerkinElmer Inc.
    • 6.1.9 Promega Corporation
    • 6.1.10 Siemens Healthcare
    • 6.1.11 Thermo Fisher Scientific Inc.
    • 6.1.12 QIAGEN
    • 6.1.13 F. Hoffmann-La Roche Ltd
    • 6.1.14 Danaher Corporation